<DOC>
	<DOC>NCT01102400</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).</brief_summary>
	<brief_title>A Study of MEDI-575 in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Having advanced solid malignancy for which no curative or standard therapies exist Karnofsky performance status of â‰¥60 Patients must have histological confirmed diagnosis of HCC with no standard therapy available (for only expansion part) Inadequate bone marrow reserve or organ function Major surgery within 4 weeks or minor surgery within 2 weeks prior to receipt of MEDI575. Patients must have no unhealed wounds or unhealed fractures History of allergy or reaction to any component of the MEDI575 and/or monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>